Which mechanisms and modalities are drawing new clinical trials? New registrations in the last 12 months compared with the 12 months before, for molecules still in development and for new kinds of medicine.
Trials first posted in each 12-month window that name one of the mechanism's investigational molecules (ChEMBL, not yet approved). Leading molecules are the ones with the most new trials this year.
New trials per modality, matched on intervention names, titles and international drug-name endings (for example -leucel for CAR-T, -vedotin for ADCs, -siran for siRNA). The tick marks the year before.
How to read this. Counts are ClinicalTrials.gov studies by the date they were first posted, last 12 months against the 12 months before. A mechanism counts a study when it names one of its molecules in development by name or code (ChEMBL); approved drugs are left out because they mostly appear as comparators. Rings: rising at least 8 new trials and +50%; emerging 2 or fewer the year before and at least 4 now; cooling down 40% or more from at least 8; steady the rest with at least 8 (5 within an area).
What it is not. Registration is not enrolment or spending, one study can name several molecules, and ChEMBL lists only part of today's pipeline, so a missing mechanism may simply be missing from ChEMBL. Modality counts are keyword matches. A trend in registrations is a research signal, not a forecast or investment advice.